2015 Grants & Awards
Grants-in-aid of research RECIPIENTS
Crohn’s and Colitis Canada's Grants-in-Aid of Research program supports Canadian inflammatory bowel disease (IBD) research. The intention of the program is to help advance prevention, treatments, health policy, and to ultimately move us closer to discovering cures for Crohn's disease and ulcerative colitis. These grants support Canadian research projects which have a defined objective and are conducted by an investigator who is either working alone or in collaboration with others. The grants are awarded for up to three years at a maximum of $125,000 per year.
The selection process for the Grants-in-Aid of Research competition is very competitive as each research proposal submitted by either a Canadian researcher or healthcare professional is thoroughly reviewed by a Grant Review Panel comprised of scientific experts and lay persons. The Grant Review Panel scores and ranks the submitted applications based on merit and relevance to the patient community.
Please find below the 2015 recipients of the Grants-in-Aid of Research.
Dr. Jean-Eric Ghia | University of Manitoba
Co-investigators: Dr. Charles Bernstein, and Dr. Abdelilah Soussi-Gounni
Using IBD patient biopsies and animal models, Dr. Ghia will study the role of Semaphorin, a secreted protein involved in COPD and arthritis, in regulating intestinal inflammation.
Dr. Stephen Girardin | University of Toronto
Co-investigators: Dr. Katrina Gee, Dr. David Reed, and Dr. Alan Lomax
Dr. Girardin will study the impact of the most common genetic mutation in IBD, NOD2, on the function of the small intestine, using a unique animal model and also organoids (“mini-guts” derived from human gut cells).
Dr. Nicola Jones | The Hospital for Sick Children
Co-investigators: Dr. Dana Philpott, and Dr. Anne Griffiths
Dr. Jones will study how vitamin D may influence IBD, by using animal models and novel intestinal mini-guts, called organoids, which mimic the normal intestine.
Dr. Alan Lomax | Queen's University
Dr. Lomax will examine how IBD affects the nervous system by studying how the bacteria in the gut and chemicals released during inflammation can impact gut neurons and ultimately devise new ways to block the neuronal changes that contribute to pain and diarrhea.
Dr. Derek McKay | University of Calgary
Dr. McKay will investigate the use autologous transplantation using cells with anti-inflammatory benefits as a personalized approach to treating IBD.
Dr. Michael Surette | McMaster University
Co-investigators: Dr. Paul Moayeddi, Dr. Walter Reinsch, and Dr. Christine Lee
Dr. Surette is trying to determine the mechanisms by which fecal transplantation works by identifying all the microorganisms (bacteria, fungi and viruses) present in UC patients before and after treatment. The goal is to make fecal transplantation more effective and accessible with fewer potential risks.
Dr. Eytan Wine | University of Alberta
Co-investigators: Dr. Leo Dieleman, Dr. Jens Walter, and Dr. Gane Wong
Date: 2015-2018 Co-funded with CCFA
Dr. Wine will be using new technologies to locate and ‘trap’ bacteria that are recognized by the patients' own immune system and likely lead to disease. The results of this research will provide new markers that could be used to help diagnose children (and later adults) with IBD and possibly to even find new treatments.
INNOVATIONS IN IBD GRANT RECIPIENTS
The Innovations in IBD Grant is a one-year grant, valued at up to $50,000 that funds novel or innovative approaches to IBD research. The grant stimulates and supports research which may not be encompassed within the boundaries of traditional medical research. This award is open to both Canadian and international applicants.
Similar to the Grants-in-Aid of Research, the selection process for the Innovations in IBD Grant competition is very competitive as each research proposal submitted by either a researcher or healthcare professional is thoroughly reviewed by a Grant Review Panel. Comprised of scientific experts and lay persons, the Grant Review Panel scores and ranks the submitted applications based on merit and relevance to the patient community.
Please find below the 2017 recipients of the Innovations in IBD Grant.
Dr. Pere Santamaria | University of Calgary
IBD is the result of a dysregulated immune response to gut bacteria. Dr. Santamaria has discovered that regulatory white blood cells targeting proteins expressed by gut bacteria can reset this balance and protect mice from colitis. This proposal will test whether the expansion of gut bacteria-specific regulatory white blood cells by treating mice with IBD-specific nanomedicines will blunt the progression of IBD, as a step towards developing a therapeutic nanomedicine for humans.
Dr. Deanna Gibson | University of British Columbia (Okanagan)
The use of probiotic bacteria is a promising IBD therapy, however clinical trials demonstrating its effectiveness have been inconsistent. Dr. Gibson is looking at ways of improving probiotic therapy by enhancing the probiotic’s ability to adhere to the gut and grow better in the inflamed gut of an IBD patient.